ARS Pharmaceuticals, Inc. (SPRY) Stock Profile — Insider Trades & Financials

Revenue$28.1M

Net Income-$41.3M

EPS$-1.32

Market Cap$813.2M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Richard Lowenthal

CEO & Executive Director

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Founded: 2015
Employees: 163
Headquarters: San Diego, California, United States
Website

⚡

Core Efficiency

ROE?

-36.17%

ROA?

-12.61%

D/E Ratio?

1.87

Op. Margin?

-147.63%

📊

Profitability Ratios

Net Margin?

-147.13%

Loading company sections...

ARS Pharmaceuticals, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness